Navigation Links
Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine"
Date:7/22/2008

A Pilot Study Suggests That Ekkyo's New Approach of LASH (Laser Assisted

Scar Healing) can Drastically Improve Scar Healing Physiology

MARSEILLES, France, July 22 /PRNewswire/ -- Ekkyo (formerly known as Heatwave Technology) a photomedicine company, which develops first-in-class laser-based systems for skin scar prevention and reduction, announced today the publication of a scientific article in Lasers in Surgery and Medicine* reporting the results of a pilot study on cutaneous scar prevention by LASH.

Based on the therapeutic effects of controlled selective hyperthermia, Ekkyo's approach aims to stimulate the natural repair mechanisms of the skin, initiated at the critical moment of wound closure (ie the thrombotic phase). This innovative approach was validated in animals by a proof of concept study performed using an 810 nm laser diode system that showed its ability to speed up the healing process and avoid visible marks of the wounds (Capon, Souil et al. 2001 Lasers Surg Med. 2001;28(2):168-75).

To demonstrate the relevance of this approach in humans, a pilot** clinical trial, focused on abdominoplasty, was carried out at the Lille University Hospital Center (in September 2006 - December 2007). Conducted by Dr. Alexandre Capon, plastic surgeon, the aim of the study was twofold: evaluating the safety, as well as the therapeutic and cosmetic benefits of a treatment by an 810 nm laser diode. This is the base for the handheld laser Ekkylite(TM) the very first Laser Assisted Scar Healing system using a "smart" safety device in charge of recognizing, setting up and defining the parameters of the laser during treatment.

"The results of this study are very encouraging; they validate our approach from the view point of safety and efficacy in a difficult clinical context of abdominal plasty that usually leaves unsightly long scars ; they impact patients self esteem and decrease the benefits of the surgical intervention," comments D
'/>"/>

SOURCE EKKYO
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. Latest Cell Publication Describes the Novel Kinase Regulators Using OriGenes Functional Kinome Collection
2. Wacker Validates Scalability of Anticalin(R) Production With E.coli Secretion Technology and Will Produce Pieris First Clinical Candidate PRS-050
3. Bapineuzumab To Become the First-to-Market Disease-Modifying Alzheimers Drug After Flurizans Discontinuation
4. Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company
5. Sonablate(R) International HIFU Registry is the First Worldwide HIFU Clinical Registry for Prostate Cancer Treatments
6. Patient Receives vProtect(TM) Luminal Shield in First-Ever Vulnerable Plaque Clinical Trial
7. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
8. First Breast Cancer Patient Receives Treatment in National Electronic Brachytherapy Registry Launched by Three Physician Societies
9. Olanzapine Long-Acting Injection (LAI) Data Presented at First Annual Schizophrenia International Research Society Conference
10. Accumetrics Announces the Launch and First Patient Enrolled Into the GRAVITAS Trial
11. Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2009)...AN DIEGO, June 30 Accumetrics, Inc...1,600 patients) in the enrollment of its landmark ...ss with A V erifyNow(R) Assay I mpact on T hrom...designed to demonstrate the value of providing cli...ho are poor responders to clopidogrel (Plavix(R))....
(Date:6/30/2009)...AN DIEGO, June 30 Calixa Therapeut... 2 clinical trial of CXA-101 in patients with comp...w broad-spectrum, parenteral cephalosporin antibio...ty against Pseudomonas aeruginosa , including dru...-101 as a potential treatment for serious bacteria...
(Date:6/29/2009)...rospective Study Seeks to Assess RSV Burden in Out...cing Commitment to Pediatric Research , , GAI...continues to advance its commitment to pediatric r...ervational prospective study designed to assess th...g preterm infants 32-to-35 weeks gestational age (...
(Date:6/29/2009)...tudy in major abdominal surgery patients achieved ...Y, Calif., June 29 AcelRx Pharmace...m the second Phase 2 clinical study evaluating the...Tabs(TM) for the management of acute post-operativ...ng hospitalization. Compared to placebo, patients ...
Breaking Medicine Technology:Accumetrics, Inc. Announces GRAVITAS Trial 50 Percent Enrolled 2Calixa Therapeutics Announces Initiation of Phase 2 Clinical Trial of Its Antibiotic, CXA-101, in Patients with Complicated Urinary Tract Infections 2MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Premature Infants 2AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 2AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 3AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 4Proton pump inhibitors increase risk of heart attacks for patients on common cardiac drug 35081 1Proton pump inhibitors increase risk of heart attacks for patients on common cardiac drug 35081 2Physically fit kids do better in school 6827 1Concordia University leads academic team for national Cellulosic Biofuels Network 6823 1Borosage Urges Progressives to Rally Around Obama Economic Recovery Plan 35077 1
...ons Across the Genome From 242,Patients and Identi...blastic Leukemia, Suggesting New Targets for Impro...swire/ -- Investigators at,St. Jude Children,s Res...ted mutations that contribute to the formation of ...most common cancer in,children. The discovery not ...
..., 2007 (CCNMatthews via COMTEX,News Network) -- Ad...pharmaceutical company with a broad portfolio of o...d that Dr. Antonella,Perotti, MD, Istituto Naziona...gator in Adherex,s European Phase Ib/II study,of s...at study at,the 5th International Symposium on Tar...
Other Medicine Technology:Major Gene Study Uncovers Secrets of Leukemia 2Major Gene Study Uncovers Secrets of Leukemia 3Data From Adherex's European Phase Ib/II Trial of ADH-1 to be,Presented at International Symposium on Targeted Anticancer,Therapies 2Data From Adherex's European Phase Ib/II Trial of ADH-1 to be,Presented at International Symposium on Targeted Anticancer,Therapies 3
(Date:7/2/2009)..., Texas Health one of 63 businesses honored in W...PRNewswire-USNewswire/ -- Texas Health Resources...styles award from the National Business Group on ...i-bin/prnh/20090702/DC41773LOGO ) , , The aw...or innovative programs that promote a healthy work...
(Date:7/2/2009)...Effective conservation can help reduce threat, ex...y News) -- Cancer is a major threat to certain spe...gh health monitoring, researchers say. , "Cance..., accounting for more than 10 percent of human dea...ld animals at similar rates," lead author Denise M...
(Date:7/2/2009)...When the sleep aid shuts down one set of neurons, ..., July 2 (HealthDay News) -- New information abou... people who take the sleep aid Ambien (zolpidem) w...ot fully awake -- and without remembering it the n...awaken minimally conscious patients into a conscio...
(Date:7/2/2009)... Several statistical and biological issues need t...ification for early detection of cancer, according...ournal of the National Cancer Institute . , The ...screening tests includes the identification of pro...initial and definitive evaluation of biomarkers fo...
Breaking Medicine News(10 mins):Health News:Texas Health Resources Recognized by National Business Group on Health as Leading Employer Promoting Healthy Lifestyles for Employees 2Health News:Texas Health Resources Recognized by National Business Group on Health as Leading Employer Promoting Healthy Lifestyles for Employees 3Health News:Cancer Endangers Some Wildlife Species 2Health News:Odd Behaviors on Ambien Linked to Brain Circuitry 2
...proved tool to treat drug-resistant HIV thanks to ...archer.// "There are many treatments for AIDS on t...ance," said Arun Ghosh (pronounced A-rune GO-sh), ... the departments of chemistry and medicinal chemis...
...n's Research Hospital have created a mouse model o... could offer clues about //the gene therapy used t...s. The disease, named as X-linked severe combined ... mutation in a gene called gamma C that obstructs ...
...osquito-borne viruses is well known; a bite on the...the blood stream. But what happens next that cause...tim. Researchers led by a Howard Hughes Medical In...a have been able to point at a genetic element whi...
...ler of the Bernhard Nocht Institute for Tropical M...larial //parasite avoids the immune system by kill...as known that after infecting man, malarial parasi...ect the red blood cells, but it was not known how ...
Other Medicine News:Health News:Research Leads to First Treatment for Drug-Resistant HIV 2Health News:Research Leads to First Treatment for Drug-Resistant HIV 3Health News:Research Leads to First Treatment for Drug-Resistant HIV 4Health News:Discovery In "Bubble Boy" Disease Gene Therapy 2Health News:Discovery In "Bubble Boy" Disease Gene Therapy 3Health News:Discovery In "Bubble Boy" Disease Gene Therapy 4Health News:The Dengue Virus Unplugged 2Health News:The Dengue Virus Unplugged 3
...EBI OsteoGen surgically implanted bone growth stim...nunions when surgery is already planned or when pa...eoGen is totally surgically implanted, patients ar... nonunion site 24 hours a day for up to 6 months. ...
Propel Cannulated Interference Screw has unique, double-helix thread provides unbiased, symmetrical starts, while limiting veering and divergence. Specially refined distal end reduces abrasion where
Cannulated Interference Screws
Cannulated Interference Screws
Medicine Products: